Future Focus: Ovarian Cancer in 2018 and Beyond

OLIVER DORIGO, M.D., PH.D.
Tuesday, December 12, 2017


Oliver Dorigo, M.D., Ph.D., Associate Professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, talks about the direction of research in the ovarian cancer field going into 2018 and beyond. He shares his excitement about trials that will further investigate the efficacy of PARP inhibitors, and focus on immunotherapy. He speaks with enthusiasm about the potential to “engineer immunity” by taking a person’s T-cells and redirecting them against tumor tissue.

Dorigo emphasizes the need for better diagnostic tools to detect ovarian cancer. “The survival rate in Stage 1 ovarian cancer, those cancers confined to the ovary, is over 90 percent,” he said. “If we can find technologies that allow us to find those ovarian cancers early on, I think we will make a huge step forward.”  
 

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2018
Intellisphere, LLC. All Rights Reserved.